Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$17.57 USD
-0.04 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $17.55 -0.02 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.57 USD
-0.04 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $17.55 -0.02 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
Myriad Genetics' (MYGN) New Platform to Advance Cancer Care
by Zacks Equity Research
Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
by Zacks Equity Research
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.
Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
by Zacks Equity Research
Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.
Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
by Zacks Equity Research
Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
by Zacks Equity Research
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
by Zacks Equity Research
Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
by Zacks Equity Research
Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.
Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.